Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma.

Yukinori KurokawaTomono KawaseAtsushi TakenoHaruna FurukawaRyo YoshiokaTakuro SaitoTsuyoshi TakahashiToshio ShimokawaHidetoshi EguchiYuichiro Doki

Published in: Annals of gastroenterological surgery (2022)

Neoadjuvant DOS chemotherapy had a sufficient antitumor effect and tolerable safety profile in patients with gastric or EGJ adenocarcinoma. The survival benefit of a neoadjuvant strategy using our DOS regimen should be validated in phase 3 trials.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
lymph node